Neuroplasticity compounds: the science behind enhancing brain function

The human brain's ability to adapt, rewire, and regenerate itself has fascinated scientists and medical professionals for generations. This remarkable property, known as neuroplasticity, represents one of the most significant discoveries in our understanding of brain function and has opened new frontiers in cognitive enhancement. As our knowledge of brain plasticity has grown, so too has interest in supplements that might enhance this natural process. 

Primary candidates for neuroplasticity supplementation

Adults seeking cognitive enhancement

Working professionals, students, and individuals involved in skill acquisition often pursue neuroplasticity supplements to bolster cognitive performance. These supplements may enhance focus, facilitate memory formation, and improve mental adaptability, particularly during periods of intensive learning or high cognitive demand. By supporting synaptic connectivity and neurotransmitter balance, such interventions can provide a cognitive edge in competitive or high-pressure environments.

Aging population

Neuroplasticity tends to decline with age, particularly after the fourth decade of life. Adults over 40 may benefit from supplements aimed at supporting healthy brain aging and preserving cognitive flexibility. When paired with regular mental exercises, such supplementation may mitigate age-related cognitive decline by promoting synaptic health, neurogenesis, and anti-inflammatory pathways in the brain. This holistic approach is particularly advantageous for maintaining memory, problem-solving skills, and adaptability in later years.

Athletes and Physical Performers

Athletes, dancers, and musicians, who rely on refined motor coordination and adaptability, represent another key group that might benefit from neuroplasticity-enhancing supplements. These individuals often engage in activities that require the brain to form and reinforce new motor patterns. By improving neural communication and enhancing brain plasticity, these supplements could support quicker learning of techniques, sharper reflexes, and better overall performance.

Recovery Support

Individuals recovering from brain injuries, strokes, or other neurological trauma may also consider neuroplasticity supplements as a complementary part of their rehabilitation regimen. Such interventions might assist the brain’s natural healing and reorganization processes, potentially accelerating recovery. However, these supplements should always be used under the guidance of medical professionals to ensure safety and appropriate integration with therapy. The combination of targeted supplementation, physical therapy, and cognitive exercises can optimize recovery outcomes by enhancing synaptic repair and neural network reformation.

The foundations

Before exploring specific supplements, it’s important to understand how neuroplasticity works. Neuroplasticity happens through a few key mechanisms:

Synaptic plasticity refers to changes in the strength of connections between neurons, which play a fundamental role in learning and memory. Long-term potentiation (LTP) strengthens these connections through repeated stimulation, enhancing signal transmission, while long-term depression (LTD) weakens them to refine neural networks by eliminating unnecessary connections. Together, LTP and LTD form the cellular foundation for how we acquire, store, and recall information.

Structural plasticity, on the other hand, involves physical changes in the brain’s architecture, such as the growth of dendrites, formation of new synapses, and even the generation of new neurons (neurogenesis) in specific areas like the hippocampus. This ability to reorganize and grow is critical for adapting to new experiences and environments, and it underscores the brain’s remarkable resilience.

Functional plasticity reflects the brain’s adaptability in reallocating functions from damaged areas to healthy ones, especially after injury or disease. This capacity enables individuals to regain lost abilities and illustrates the brain’s inherent flexibility to compensate for deficits.

At the molecular level, neuroplasticity is driven by intricate cascades of cellular signals and genetic regulation. Brain-derived neurotrophic factor (BDNF), often described as “fertilizer for the brain,” is vital for neuronal survival, synaptic formation, and neurogenesis. Its role in learning, memory, and higher cognitive functions makes it a key player in maintaining brain health. Similarly, nerve growth factor (NGF) supports the growth and repair of neurons, particularly in cholinergic neurons linked to attention and memory. Neurotransmitters like glutamate, dopamine, and serotonin also mediate communication between neurons and are crucial for neuroplasticity-related processes, influencing learning, mood, and motivation.

Another critical aspect of neuroplasticity involves astrocytes and microglia, glial cells traditionally viewed as mere support structures for neurons but now recognized for their active roles in synaptic plasticity. Astrocytes regulate neurotransmitter clearance and provide metabolic support, while microglia are involved in synaptic pruning, clearing away underused connections to refine neural networks. Dysregulation of these processes has been implicated in neurological and psychiatric disorders.

Additionally, mitochondrial health is emerging as a key factor in neuroplasticity. Neurons rely heavily on energy from mitochondria to support the high metabolic demands of synaptic remodeling and neurogenesis. Impaired mitochondrial function can lead to reduced plasticity and cognitive decline, highlighting the importance of metabolic support for brain health.

Core supplements for enhancing neuroplasticity 

Omega-3 Fatty Acids (DHA and EPA) 

Omega-3 fatty acids, particularly DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid), are essential for maintaining brain health. These fatty acids are key components of cell membranes, especially in the brain, where they influence neuroplasticity in several ways. DHA increases membrane fluidity, which allows for better signal transmission between neurons. Additionally, omega-3s upregulate genes involved in synaptic plasticity and reduce neuroinflammation, a factor that can impair plasticity when left unchecked.

A meta-analysis published in Clinical Nutrition ESPEN examines how omega-3 supplementation affects serum levels of brain-derived neurotrophic factor (BDNF), a critical protein for neuroplasticity. By aggregating data from multiple trials, the study found that omega-3 supplementation leads to a consistent and significant increase in BDNF levels compared to control groups. Importantly, the analysis also emphasizes that the dosage and duration of supplementation matter. Doses of 1,500 mg per day or less, taken over a period of 10 weeks or more, yield the most pronounced increases in BDNF. This suggests that sustained, moderate omega-3 supplementation is optimal for enhancing neuroplasticity.

Another systematic review, published in Nutrients, explores the role of omega-3 fatty acids in promoting brain health across different stages of life. This review synthesizes evidence from a wide range of studies, focusing on omega-3’s impact on neuroplasticity, cognitive performance, and the prevention of neurological disorders. It highlights the essential role of omega-3s in maintaining the structural and functional integrity of the brain. The review also discusses omega-3’s ability to upregulate BDNF levels and its anti-inflammatory properties.

Chronic neuroinflammation is a hallmark of several neurodegenerative diseases, including Alzheimer’s and Parkinson’s. By reducing inflammation and oxidative stress, omega-3 supplementation may help prevent or mitigate these conditions. The review further underscores the importance of omega-3 intake during early developmental stages for optimal brain development and later in life to counteract age-related cognitive decline.

Optimal usage: omega-3 fatty acids show promise not only as a preventive measure but also as a therapeutic tool for enhancing neuroplasticity and cognitive performance in various populations. For optimal benefits, a daily dose of 1,000–2,000 mg of combined EPA/DHA is recommended, with the best results observed at 1,500 mg per day taken over at least 10 weeks. These supplements should be consumed with meals containing healthy fats to improve absorption.

Lion’s Mane

Lion’s Mane Mushroom, scientifically known as Hericium erinaceus, contains bioactive compounds called hericenones and erinacines. These compounds can cross the blood-brain barrier and stimulate the production of nerve growth factor (NGF), a protein essential for the growth, survival, and maintenance of neurons. Lion’s Mane promotes myelination of nerve fibers, supports neuronal survival, and enhances neural regeneration, making it a valuable supplement for brain and nerve health.

Research has demonstrated its effectiveness in cognitive and nerve-related outcomes. A double-blind, parallel-group, placebo-controlled trial conducted with 30 Japanese adults aged 50–80 years showed significant improvements in cognitive function after 16 weeks of Lion’s Mane supplementation. Another study highlighted its role in promoting nerve regeneration, particularly in individuals with peripheral nerve injuries, indicating its potential for recovery and rehabilitation.

Optimal usage: Lion’s Mane mushroom is typically consumed as a standardized extract, with a daily dosage of 500–1,000 mg being common. Higher doses, up to 3,000 mg per day, have been studied and found to be safe without major adverse effects. Users may begin to notice improvements within 2–3 weeks of consistent supplementation.

Magnesium L-Threonate

Magnesium L-threonate (MgT) is a specialized form of magnesium designed to cross the blood-brain barrier, making it particularly effective for supporting brain health and central nervous system functions. Studies have shown its potential to enhance neuroplasticity, protect against neurodegeneration, and improve cognitive abilities.

A study published in Molecular Brain investigated the effects of MgT on synaptic density and cognitive function in a transgenic mouse model of Alzheimer’s disease. MgT supplementation was found to increase brain magnesium levels, preventing synapse loss and improving memory performance. These benefits are linked to the activation of signaling pathways involving NMDAR (N-methyl-D-aspartate receptor), a key receptor for learning and memory. Additionally, MgT regulated BACE1, a protein involved in the production of amyloid-beta plaques. By controlling BACE1, MgT reduced the formation of amyloid plaques, protecting against further cognitive decline.

Research published in The Journal of Neuroscience examined MgT’s role in enhancing synaptic plasticity and memory in rats. The study demonstrated that MgT supplementation increased synaptic density in the hippocampus, a critical brain region for learning and memory. This led to significant improvements in learning and memory tasks. Notably, MgT also facilitated the extinction of fear memories without erasing the original fear memory, suggesting potential applications in treating anxiety disorders and post-traumatic stress disorder (PTSD).

A review in Frontiers in Endocrinology highlighted MgT’s ability to combat neuroinflammation and neurodegeneration. By increasing synaptic density and promoting synaptic plasticity, MgT may mitigate cognitive decline associated with aging and neurodegenerative conditions. The review also emphasized MgT’s role in reducing neuroinflammatory processes, further protecting brain health.

Optimal Usage: For maximum efficacy, MgT is best taken at a daily dose of 1,500–2,000 mg, divided into two or three doses. This ensures consistent absorption while minimizing the risk of gastrointestinal side effects.

Uridine

Uridine, a naturally occurring nucleoside, plays a vital role in brain health by supporting neuroplasticity, synaptic function, and cognitive performance. Research highlights its efficacy in improving memory and protecting against cognitive decline, especially when combined with other nutrients like DHA and choline.

A study published in FASEB Journal investigated the effects of uridine monophosphate (UMP) supplementation on gerbils. The gerbils were divided into two groups: one received a diet enriched with UMP, choline, and DHA, while the control group was fed a standard diet. Over several weeks, cognitive performance was assessed using maze navigation tests. The supplemented group showed significant improvements in spatial learning and memory. These benefits were linked to increased synaptic membrane synthesis in brain regions crucial for cognition, demonstrating uridine’s role in enhancing brain function.

A study in Neurology and Therapy examined the impact of a multinutrient supplement containing uridine, choline, and DHA on individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease. Participants received the supplement daily for six months. Cognitive tests and MRI scans were conducted at the start and end of the study. The results showed that those taking the supplement had a slower rate of brain atrophy compared to the control group. Additionally, improvements in cognitive performance were observed in the supplement group. These findings suggest that uridine, particularly when combined with DHA and choline, may help delay the progression of Alzheimer’s disease by preserving brain structure and enhancing cognitive function.

Optimal usage: For effective supplementation, uridine monophosphate (UMP) is recommended at a daily dose of 150–300 mg. Combining UMP with DHA and choline is particularly beneficial for enhancing neuroplasticity and cognitive health.

Phosphatidylserine

Phosphatidylserine (PS) is a phospholipid that plays an essential role in the structural and functional integrity of neuronal cell membranes. It is particularly vital for cognitive functions and neuroplasticity, helping the brain adapt to new information and maintain optimal mental performance.

A 12-week double-blind, placebo-controlled trial evaluated the effects of PS supplementation on memory in adults aged 50 to 90 years experiencing memory complaints. Participants who received 300 mg of PS daily showed significant improvements in memory recall, recognition, and mental flexibility compared to the placebo group. These findings suggest that PS supplementation can enhance cognitive function, particularly in older individuals experiencing age-related memory decline.

Research shows that PS promotes neuroplasticity by facilitating the growth of dendrites, the branching extensions of neurons that receive signals. This dendritic growth enhances the brain’s ability to form new neural connections, which is critical for learning and memory. Furthermore, PS has been shown to stimulate the production of nerve growth factor (NGF), which supports the formation and maintenance of neurons, further contributing to brain health and adaptability.

A review article highlighted PS’s involvement in various brain functions, including the activation of membrane signaling pathways, modulation of neuroinflammation, and enhancement of synaptic function. PS supplementation has been shown to improve cognitive impairments associated with aging and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. Its anti-inflammatory properties also contribute to its neuroprotective effects, making it a potential therapeutic agent for managing these conditions.

Optimal usage: For maximum effectiveness, PS is typically taken in doses of 100–300 mg daily, divided into 1–3 doses. It is best consumed with meals to enhance bioavailability and ensure optimal absorption.

Advanced and less studied options

ARA 290, also known as cibinetide, is an 11-amino acid peptide derived from erythropoietin (EPO). Unlike EPO, ARA 290 does not stimulate red blood cell production but selectively activates the innate repair receptor (IRR). This activation drives its tissue-protective and anti-inflammatory properties, making it a promising therapeutic agent for various conditions involving nerve damage and inflammation.

A clinical trial investigated ARA 290’s effects in patients with sarcoidosis experiencing small fiber neuropathy (SFN). Participants received daily subcutaneous injections of ARA 290 or a placebo for 28 days. The ARA 290 group experienced significant reductions in neuropathic pain and an improvement in corneal nerve fiber density, suggesting enhanced nerve regeneration. Importantly, no serious adverse effects were reported, supporting the safety and efficacy of ARA 290 for SFN treatment in sarcoidosis patients.

Animal studies provide further support for ARA 290’s potential. In rodent models of nerve injury, ARA 290 administration enhanced nerve regeneration and functional recovery. The peptide reduced inflammation and apoptosis at the injury site, creating an environment conducive to nerve repair. These findings highlight its therapeutic promise for peripheral nerve injuries. Research in diabetic rodent models, on the other hand, demonstrated ARA 290’s ability to mitigate retinal inflammation and preserve neural retinal structure and function. By modulating inflammatory mediators, the peptide may help prevent or slow the progression of diabetic retinopathy, a common complication of diabetes that affects the eyes.

Optimal Usage: ARA 290 is typically administered subcutaneously at doses of 2–8 mg daily over a short treatment course, such as 28 days. It is primarily used for conditions like neuropathic pain and nerve regeneration, though ongoing research may expand its applications in the future.

Cortagen

Cortagen is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Pro, derived from the natural brain cortex peptide preparation Cortexin. It has demonstrated neuroprotective and neurotrophic properties, with particular promise in promoting nerve regeneration and modulating gene expression related to neural repair and function.

A study on sciatic nerve regeneration in rats investigated Cortagen’s efficacy in promoting peripheral nerve repair. Following sciatic nerve transection and surgical suturing, rats received intramuscular injections of Cortagen at a dose of 10 µg/kg daily for 10 days. The treatment led to a 27% increase in nerve growth rate and a 40% improvement in conduction velocity in regenerating nerve fibers compared to controls. These findings highlight Cortagen’s potential to significantly enhance the repair of peripheral nerves.

Research into the psychoactive effects of Cortagen involved administering the peptide to rodents and observing changes in locomotor activity and anxiety-like behaviors. The peptide was found to increase locomotion and reduce anxiety-like behaviors, possibly due to its stimulation of neurotrophic factors. This suggests that Cortagen may also have applications in modulating mood and behavior, providing benefits beyond physical nerve repair.

Cortagen’s effects are likely mediated through its ability to influence the expression of genes involved in neuroprotection, nerve growth, and synaptic plasticity. Its neurotrophic effects may involve enhancing the release of neurotrophic factors, critical proteins for neuron survival and function.
Optimal Usage: cortagen is typically administered intranasally at a dose of 400–1,000 µg daily for 10 days. This regimen is commonly used in clinical settings for applications related to nerve regeneration and neuroprotection. Further studies are needed to confirm its long-term safety and efficacy across different populations and conditions.

P21

P21, also known as P021, is a synthetic peptide derived from ciliary neurotrophic factor (CNTF) that has gained attention for its potential neuroprotective and cognitive-enhancing properties. It has shown promise in addressing neurodegenerative conditions such as Alzheimer’s disease (AD) and age-related cognitive decline by promoting neurogenesis, improving synaptic plasticity, and reducing pathological markers.

In studies involving 3xTg-AD mice, a well-established model for Alzheimer’s disease, P21 administration was found to enhance neurogenesis in the dentate gyrus, a brain region critical for memory formation. The peptide also improved memory functions in these mice by inhibiting the leukemia inhibitory factor (LIF) signaling pathway and increasing brain-derived neurotrophic factor (BDNF) expression. BDNF is a key protein involved in supporting the survival and growth of neurons, and its upregulation contributes to P21’s neuroprotective effects.

Research on aged laboratory rats further demonstrated P21’s ability to address age-related cognitive decline. Oral administration of P21 reduced levels of total tau protein in the brain, aligning them with those observed in younger rats. Tau protein abnormalities are a hallmark of Alzheimer’s disease and contribute to synaptic and neuronal dysfunction. Treatment with P21 not only lowered tau levels but also rescued deficits in dendritic and synaptic function. Additionally, P21 promoted neurogenesis and reversed cognitive impairments, highlighting its therapeutic potential for aging-related neurological conditions.

The mechanisms underlying P21’s effects include the inhibition of LIF signaling, which is associated with inflammation and neurodegeneration, and the upregulation of BDNF, which enhances synaptic plasticity and cognitive function. By reducing abnormal tau levels, P21 also mitigates synaptic damage, contributing to its neuroprotective role.

Optimal usage: P21 is typically administered at doses of 200–500 mcg daily, either subcutaneously or intranasally, for its cognitive-enhancing and neuroprotective benefits. While the results from preclinical studies are promising, further clinical trials are needed to validate P21’s efficacy and safety in humans.

Cerebrolysin

Cerebrolysin is a neuropeptide preparation derived from porcine brain proteins, containing low-molecular-weight peptides and amino acids. It has been extensively studied for its neuroprotective and neurotrophic effects, particularly in treating neurodegenerative diseases, traumatic brain injuries (TBI), and acute brain injuries such as stroke.

A systematic review and meta-analysis published in Pharmaceuticals evaluated the safety and efficacy of Cerebrolysin in acute ischemic stroke patients. The findings confirmed that Cerebrolysin is safe for neurorecovery and did not significantly increase adverse events compared to placebo. In the CAPTAIN II trial, a phase IIIb/IV randomized, double-blind, placebo-controlled study, Cerebrolysin was shown to improve neurorecovery outcomes in moderate to severe TBI patients. These improvements included enhanced cognitive and motor functions, with no significant safety concerns, suggesting its potential as an adjunct therapy for TBI management.

Research published in Frontiers in Neurology investigated the effects of Cerebrolysin on patients in a minimally conscious state following a stroke. The study suggested that Cerebrolysin might improve consciousness levels, though further clinical trials are needed to confirm these findings. Additionally, a meta-analysis in Dementia and Geriatric Cognitive Disorders demonstrated that Cerebrolysin outperformed placebo in improving cognitive function and overall clinical outcomes in patients with mild to moderate Alzheimer’s disease, highlighting its potential as a therapeutic option for Alzheimer’s management.

Optimal usage: Cerebrolysin works by supporting neuronal survival and repair, enhancing synaptic plasticity, and reducing oxidative stress and neuroinflammation. It is typically administered via intravenous infusion or intramuscular injection at doses of 2 to 10 mL daily over a period of 10–20 days, depending on the condition being treated. Longer treatment courses may be recommended for chronic conditions such as Alzheimer’s disease. Continued research is essential to further validate Cerebrolysin’s applications and optimize its use across various patient populations.

7,8-DHF – tropoflavin 

7,8-Dihydroxyflavone (7,8-DHF), also known as tropoflavin, is a naturally occurring flavonoid that acts as a selective agonist for the tropomyosin receptor kinase B (TrkB), the primary receptor for brain-derived neurotrophic factor (BDNF). By mimicking BDNF, it exhibits significant neuroprotective and cognitive-enhancing properties, with potential applications in treating various neurological and psychiatric conditions.

In a rat model of vascular dementia induced by permanent bilateral carotid artery occlusion, 7,8-DHF administration at doses of 5, 10, and 20 mg/kg over four weeks improved cognitive deficits. The treatment alleviated cholinergic dysfunction, reduced inflammation, and decreased oxidative stress, highlighting its potential for managing vascular dementia. Additional studies in rodents demonstrated that 7,8-DHF countered helplessness behaviors and increased resilience to social defeat stress. These findings suggest that 7,8-DHF addresses core BDNF deficiencies, showing promise as an antidepressant and mood stabilizer.

In preclinical models of Alzheimer’s disease, 7,8-DHF was beneficial due to its TrkB receptor agonist activity. While it did not increase the number of new neurons in aged animals, it enhanced dendritic length in newborn neurons in the hippocampus, a region crucial for learning and memory. This action suggests its utility in preserving cognitive function and mitigating neurodegeneration. Moreover, 7,8-DHF has been found to reduce neuronal death and support neurogenesis, showing promise for treating cognitive impairments resulting from traumatic or ischemic brain injuries.

Optimal usage: 7,8-DHF is typically used at doses of 10–30 mg daily, taken in one or two doses. It is best consumed on an empty stomach or with a small meal to enhance absorption. Further research is warranted to validate its efficacy and optimize its applications in human populations.

Noopept

Noopept, chemically known as N-phenylacetyl-L-prolylglycine ethyl ester, is a synthetic nootropic compound developed for its potential to enhance cognitive function and provide neuroprotective benefits. Although structurally related to the racetam family of nootropics, Noopept is significantly more potent and has gained popularity for its ability to improve memory, focus, and overall brain health.

Research suggests that Noopept enhances cognitive function through its influence on neurotransmitter systems, particularly the acetylcholine and glutamate pathways. These pathways play critical roles in learning, memory, and attention. Noopept also promotes the production of neurotrophic factors like brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which support neuronal growth, repair, and synaptic plasticity, making it a promising agent for improving long-term cognitive function and resilience.

Optimal usage: noopept is typically taken at doses of 10–30 mg per day, divided into two doses. For improved absorption, it can be administered sublingually or with food. As with any nootropic, consistent use over time is recommended to maximize its cognitive and neuroprotective benefits, though further studies are warranted to fully understand its long-term effects.

Wrapping up

In the end, enhancing your brain’s adaptability isn’t about one single trick—it’s about the everyday choices you make. When you expose yourself to new challenges—whether that’s tackling a fresh subject, learning an instrument, or simply exploring a different route through your daily routine—you give your neurons a reason to form new connections. Pair that curiosity with regular movement, restorative sleep, balanced nutrition, and moments of genuine relaxation, and you create the ideal environment for those connections to strengthen.

For moments when life throws unexpected hurdles—aging, injury, stress—you can lean on targeted support, from evidence-based supplements to guided therapies, always under the care of professionals. But the real power lies in consistency: approaching each day as an opportunity to learn, to rest well, to nourish both body and mind, and to manage stress in ways that feel authentic to you. Over time, these habits add up, keeping your cognitive abilities sharp, your memory resilient, and your capacity for learning firmly intact—no shortcuts required.